Sampathkumar P, Drage LA, Martin DP. Herpes zoster (shingles) and postherpetic neuralgia. Mayo Clin Proc. 2009;84(3):274–80. https://doi.org/10.4065/84.3.274.

Article  PubMed  PubMed Central  Google Scholar 

Curran D, Callegaro A, Fahrbach K, Neupane B, Vroling H, van Oorschot D, et al. Meta-regression of herpes zoster incidence worldwide. Infect Dis Ther. 2022;11(1):389–403. https://doi.org/10.1007/s40121-021-00567-8.

Article  PubMed  Google Scholar 

Chen SY, Suaya JA, Li Q, Galindo CM, Misurski D, Burstin S, et al. Incidence of herpes zoster in patients with altered immune function. Infection. 2014;42(2):325–34. https://doi.org/10.1007/s15010-013-0550-8.

Article  CAS  PubMed  Google Scholar 

Government of Canada. Herpes zoster (shingles) vaccine: Canadian Immunization Guide. 2018. Available at: https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-8-herpes-zoster-(shingles)-vaccine.html. Accessed 18 Jan 2023.

Varghese L, Standaert B, Olivieri A, Curran D. The temporal impact of aging on the burden of herpes zoster. BMC Geriatr. 2017;17(1):30. https://doi.org/10.1186/s12877-017-0420-9.

Article  PubMed  PubMed Central  Google Scholar 

Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82(11):1341–9. https://doi.org/10.4065/82.11.1341.

Article  PubMed  Google Scholar 

Liesegang TJ. Herpes zoster ophthalmicus natural history, risk factors, clinical presentation, and morbidity. Ophthalmology. 2008;115(2 Suppl):S3–12. https://doi.org/10.1016/j.ophtha.2007.10.009.

Article  PubMed  Google Scholar 

Minor M, Payne E. Herpes zoster ophthalmicus. Treasure Island: StatPearls; 2022.

Google Scholar 

Johnson RW, Bouhassira D, Kassianos G, Leplege A, Schmader KE, Weinke T. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med. 2010;8(1):37. https://doi.org/10.1186/1741-7015-8-37.

Article  PubMed  PubMed Central  Google Scholar 

Drolet M, Brisson M, Schmader KE, Levin MJ, Johnson R, Oxman MN, et al. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. CMAJ. 2010;182(16):1731–6. https://doi.org/10.1503/cmaj.091711.

Article  PubMed  PubMed Central  Google Scholar 

National Advisory Committee on Immunization (NACI). Statement on the recommended use of herpes zoster vaccine. 2010. Available at: https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2010-36/canada-communicable-disease-report.html. Accessed 30 Jan 2023.

Warrington R, Ismail S, National Advisory Committee on Immunization (NACI). Summary of the NACI update on herpes zoster vaccines. Can Commun Dis Rep. 2018;44(9):220–5. https://doi.org/10.14745/ccdr.v44i09a06.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Drug Shortages Canada. Discontinuation report ZOSTAVAX II. Available at: https://www.drugshortagescanada.ca/discontinuance/159386. Accessed 1 May 2023.

McGirr A, Van Oorschot D, Widenmaier R, Stokes M, Ganz ML, Jung H, et al. Public health impact and cost-effectiveness of non-live adjuvanted recombinant zoster vaccine in Canadian adults. Appl Health Econ Health Policy. 2019;17(5):723–32. https://doi.org/10.1007/s40258-019-00491-6.

Article  PubMed  PubMed Central  Google Scholar 

Boutry C, Hastie A, Diez-Domingo J, Tinoco JC, Yu CJ, Andrews C, et al. The adjuvanted recombinant zoster vaccine confers long-term protection against herpes zoster: interim results of an extension study of the pivotal phase 3 clinical trials ZOE-50 and ZOE-70. Clin Infect Dis. 2022;74(8):1459–67. https://doi.org/10.1093/cid/ciab629.

Article  CAS  PubMed  Google Scholar 

Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Diez-Domingo J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375(11):1019–32. https://doi.org/10.1056/NEJMoa1603800.

Article  CAS  PubMed  Google Scholar 

Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087–96. https://doi.org/10.1056/NEJMoa1501184.

Article  PubMed  Google Scholar 

Curran D, Van Oorschot D, Varghese L, Oostvogels L, Mrkvan T, Colindres R, et al. Assessment of the potential public health impact of herpes zoster vaccination in Germany. Hum Vaccin Immunother. 2017;13(10):2213–21. https://doi.org/10.1080/21645515.2017.1345399.

Article  PubMed  PubMed Central  Google Scholar 

Curran D, Patterson B, Varghese L, Van Oorschot D, Buck P, Carrico J, et al. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States. Vaccine. 2018;36(33):5037–45. https://doi.org/10.1016/j.vaccine.2018.07.005.

Article  CAS  PubMed  Google Scholar 

Watanabe D, Mizukami A, Holl K, Curran D, Van Oorschot D, Varghese L, et al. The potential public health impact of herpes zoster vaccination of people aged ≥ 50 years in Japan: results of a Markov model analysis. Dermatol Ther (Heidelb). 2018;8(2):269–84. https://doi.org/10.1007/s13555-018-0236-3.

Article  PubMed  PubMed Central  Google Scholar 

van Oorschot DAM, Hunjan M, Bracke B, Lorenc S, Curran D, Starkie-Camejo H. Public health impact model estimating the impact of introducing an adjuvanted recombinant zoster vaccine into the UK universal mass vaccination programme. BMJ Open. 2019;9(5): e025553. https://doi.org/10.1136/bmjopen-2018-025553.

Article  PubMed  PubMed Central  Google Scholar 

Shiragami M, Mizukami A, Kaise T, Curran D, Van Oorschot D, Bracke B, et al. Cost-effectiveness of the adjuvant recombinant zoster vaccine in Japanese adults aged 65 years and older. Dermatol Ther (Heidelb). 2019;9(2):281–97. https://doi.org/10.1007/s13555-019-0291-4.

Article  PubMed  PubMed Central  Google Scholar 

Volpi A, Boccalini S, Dari S, Clarke C, Curran D, Loiacono I, et al. The potential public health impact of herpes zoster vaccination in the 65 years of age cohort in Italy. Hum Vaccin Immunother. 2020;16(2):327–34. https://doi.org/10.1080/21645515.2019.1657753.

Article  PubMed  Google Scholar 

Curran D, Van Oorschot D, Matthews S, Hain J, Salem AE, Schwarz M. Long-term efficacy data for the recombinant zoster vaccine: Impact on public health and cost effectiveness in Germany. Hum Vaccin Immunother. 2021;17(12):5296–303. https://doi.org/10.1080/21645515.2021.2002085.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee C, Jiang N, Tang H, Ye C, Yuan Y, Curran D. Potential public health impact of the adjuvanted recombinant zoster vaccine among people aged 50 years and older in Beijing. Hum Vaccin Immunother. 2021;17(10):3735–46. https://doi.org/10.1080/21645515.2021.1932216.

Article  PubMed  PubMed Central  Google Scholar 

Teng L, Mizukami A, Ng C, Giannelos N, Curran D, Sato T, et al. Cost-effectiveness analysis update of the adjuvanted recombinant zoster vaccine in Japanese older adults. Dermatol Ther (Heidelb). 2022;12(6):1447–67. https://doi.org/10.1007/s13555-022-00744-8.

Article  PubMed  PubMed Central  Google Scholar 

Statistics Canada. Population estimates on July 1st, by age and sex. 2022. Available at: https://doi.org/10.25318/1710000501-eng. Accessed 31 Mar 2022.

Statistics Canada. Mortality rates, by age group. 2022. Available at: https://doi.org/10.25318/1310071001-eng. Accessed 31 Mar 2022.

Marra F, Chong M, Najafzadeh M. Increasing incidence associated with herpes zoster infection in British Columbia, Canada. BMC Infect Dis. 2016;16(1):589. https://doi.org/10.1186/s12879-016-1898-z.

Article  PubMed  PubMed Central  Google Scholar 

Drolet M, Brisson M, Schmader K, Levin M, Johnson R, Oxman M, et al. Predictors of postherpetic neuralgia among patients with herpes zoster: a prospective study. J Pain. 2010;11(11):1211–21. https://doi.org/10.1016/j.jpain.2010.02.020.

Article  PubMed  Google Scholar 

Brisson M. Estimating the number needed to vaccinate to prevent herpes zoster-related disease, health care resource use and mortality. Can J Public Health. 2008;99(5):383–6. https://doi.org/10.1007/BF03405246.

Article  PubMed  PubMed Central  Google Scholar 

IQVIA. Estimated Shingrix immunization rate from IQVIA CompuScript NRx (March 2022 DM) and IQVIA GPM by Payer (March 2022 DM), both for the Canadian Shingles market. All Rights Reserved; GSK Internal Sales Data (March 2022 DM) for the Canadian Shingles market, as well as population data published by Statistics Canada. The statements, findings, conclusions, views, and opinions contained and expressed in this report are based only in part on data obtained under license from IQVIA Solutions Canada Inc. (IQVIA), and therefore such statements, findings, conclusions, views, and opinions are not necessarily those of IQVIA or any of its affiliated or subsidiary entities. Durham, NC; IQVIA

McGirr A, Bourgoin T, Wortzman M, Millson B, McNeil SA. An early look at the second dose completion of the recombinant zoster vaccine in Canadian adults: a retrospective database study. Vaccine. 2021;39(25):3397–403. https://doi.org/10.1016/j.vaccine.2021.04.053.